ALK and neoplasm: Overall, next-generation ALK inhibitors, through structural optimization and enhanced pharmacologic profiles, hold the potential not only to overcome existing resistance barriers but also to enable precise modulation of tumor biology, ultimately improving therapeutic efficacy and tolerability.